The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Criteria for the diagnosis of accelerated/blast phase MPN and challenges clinicians may face
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses the criteria and challenges associated with diagnosing accelerated/blast-phase myeloproliferative neoplasms (MPN-AP/BP). Blast percentage is used as a diagnostic tool, with those in the AP categorized as having 10-19% of blasts in the bone marrow or blood and BP classified as more than 20%. Molecular testing is important for managing MPN-AP/BP, as the type of mutation present may help with treatment selection going forward. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria:BMS, AbbVie, Sobi; Research funding (institutional): Pfizer, Sumitomo, Kronos Bio.
